Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced that members of the Board of Directors and Executive Management have purchased shares in the company.
The following share purchases have been reported:
|Shares purchased||Total shareholding|
|Peter Høngaard Andersen||Chairman of the Board||6,500||59,565|
|Jørgen Bardenfleth||Vice-chairman of the Board||15,000||425,629|
|Christian Vinding Thomsen||Board member||10,000||10,000|
|Thomas Feldthus||Board member||10,000||28,182|
|Martin Møller||Board member||4,700||4,700|
|Bo Rode Hansen||Board member & CEO||2,042||42,442|
|Annie Rasmussen||Employee representative||1,205||20,000|
Persons under an obligation to report are defined as members of the Board of Directors and members of Executive Management.
For further information regarding Scandion Oncology, please contact:
Bo Rode Hansen, President & CEO
Phone: +45 3810 2017
The information was provided by the contact person above for publication on November 22, 2021, at 17.30 CET.
Scandion Oncology A/S is a clinical Phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add-on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden.
Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at email@example.com or +46 (0) 40 200 250.